ReviewMedicine2026
Visual analysis of research status and hotspots of Panax notoginseng from 2000 to 2023: A bibliometric review.
Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPanax notoginseng is the most widely used Chinese medicine for preventing and treating ischemic diseases. Because of its good clinical efficacy, high safety, and few adverse reactions, some countries (e.g., the United States, South Korea, Japan, and Australia) have paid it increasing attention, and the number of related studies is also increasing. However, relevant studies are scattered and fragmented, and few systematic summaries and rounded analyses have been conducted. Thus, in this study, we collect and analyze data from the published literature to help researchers understand the research situation in the field and explore research hotspots and frontiers.
methodsSearch and download the literature on Panax notoginseng research published from 2000 to 2023 from 3 English databases. We used VOSviewer, Microsoft Excel, and CiteSpace to visually analyze annual publishing trends, publishing countries, institutions, authors, journals, keywords, and references in the field.
resultsA total of 1329 papers were included. The number of papers increased every year, especially in 2022. The leading countries in this field are China, the United States, and South Korea. Kunming University of Science & Technology published the most papers. Most publications were found in the Journal of Ethnopharmacology. The most prolific author is Wan Jian-Bo. Keywords with the highest frequency were Panax notoginseng, saponins, ginseng, and Panax notoginseng saponin. Eleven clusters and 25 burst keywords were generated.
conclusionsTo date, the research focus in this field has primarily focused on 4 aspects: research on pharmacologic components and quality control, mechanism of action and pathway target research, investigation of applicable diseases and therapeutic effects, and research on cultivation and yield increase. At the same time, research on microscopization, normalization, standardization, and objectification of traditional Chinese medicine is also developing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.